首页> 外文期刊>Comparative Effectiveness Research >Monotherapy of androgen deprivation therapy versus radical prostatectomy among veterans with localized prostate cancer: comparative effectiveness analysis of retrospective cohorts
【24h】

Monotherapy of androgen deprivation therapy versus radical prostatectomy among veterans with localized prostate cancer: comparative effectiveness analysis of retrospective cohorts

机译:局部前列腺癌退伍军人中雄激素剥夺疗法与根治性前列腺切除术的单一疗法:回顾性队列研究的比较有效性分析

获取原文
           

摘要

Background: This retrospective cohort study aimed to examine the comparative effectiveness of monotherapy of primary androgen deprivation therapy or radical prostatectomy.Methods: Male patients with localized prostate cancer (T1-T2, N0, M0) were identified in the Veterans Affairs Veterans Integrated Service Network 16 data warehouse (January 2003 to June 2006), with one-year baseline and at least three-year follow-up data (until June 2009). Patients were required to be 18–75 years old and without other recorded cancer history. The initiation of primary androgen deprivation therapy or monotherapy of radical prostatectomy within six months after the first diagnosis of prostate cancer was used as the index date. Primary androgen deprivation therapy patients were matched to the radical prostatectomy patients via propensity score, which was predicted from a logistic regression of treatment selection (primary androgen deprivation therapy versus radical prostatectomy) on age, race, marital status, insurance type, cancer stage, Charlson comorbidity index, and alcohol and tobacco use. The overall survival from initiation of index treatment was then analyzed using the Kaplan–Meier and Cox proportional hazards model.Results: The two cohorts were well matched at baseline (all P > 0.05). During a median follow-up of 4.3 years, the cumulative incidence of death was 13 (10.57%) among 123 primary androgen deprivation therapy patients and four (3.25%) among 123 radical prostatectomy patients (P < 0.05). The overall three-year survival rate was 92.68% for primary androgen deprivation therapy and 98.37% for radical prostatectomy (P < 0.05). Patients who received primary androgen deprivation therapy had almost three times as high a mortality risk as those using radical prostatectomy (hazards ratio 3.388, 95% confidence interval 1.094–10.492, P = 0.034).Conclusion: After propensity score matching, overall three-year survival rate following radical prostatectomy among patients with localized prostate cancer was significantly higher than that after primary androgen deprivation therapy.
机译:背景:这项回顾性队列研究旨在检验单一雄激素剥夺疗法或根治性前列腺切除术单药治疗的相对有效性。方法:在退伍军人事务退伍军人综合服务网络中识别出患有局部前列腺癌(T1-T2,N0,M0)的男性患者16个数据仓库(2003年1月至2006年6月),具有一年的基线和至少三年的跟踪数据(至2009年6月)。要求患者年龄为18-75岁,且无其他癌症史记录。首次诊断前列腺癌后六个月内开始一级雄激素剥夺疗法或根治性前列腺切除术的单一疗法作为指标日期。原发性雄激素剥夺疗法的患者通过倾向评分与前列腺癌根治术患者相匹配,这是根据年龄,种族,婚姻状况,保险类型,癌症分期,查尔森等治疗选择(原发性雄激素剥夺疗法与根治性前列腺切除术)的对数回归预测的合并症指数,以及烟酒使用情况。然后使用Kaplan–Meier和Cox比例风险模型分析了从开始进行索引治疗后的总体生存期。结果:两个队列在基线时匹配良好(所有P> 0.05)。在4.3年的中位随访期间,在123例原发性雄激素剥夺治疗患者中,死亡的累计发生率为13(10.57%),在123例前列腺癌根治性切除术患者中为4(3.25%)(P <0.05)。初次雄激素剥夺治疗的总三年生存率为92.68%,根治性前列腺切除术的总三年生存率为98.37%(P <0.05)。接受原发性雄激素剥夺治疗的患者的死亡风险几乎是采用根治性前列腺切除术的患者的三倍(危险比3.388,95%置信区间1.094-10.492,P = 0.034)。结论:倾向评分匹配后,总体三年局限性前列腺癌患者根治性前列腺切除术后的生存率显着高于原发性雄激素剥夺治疗后的生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号